Rashida Z. Mustafa

Medicine · Health Sciences

5h-index641citations30works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(28), Lymphoma Diagnosis and Treatment(20), Galectins and Cancer Biology(14), Chronic Myeloid Leukemia Treatments(9), Monoclonal and Polyclonal Antibodies Research(6)

Publications30 total

Supplementary Figure S4 from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <i>In Vivo</i>
2023Open Access
Supplementary Table S3 from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <i>In Vivo</i>
2023Open Access
Supplementary Figure Legends from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <i>In Vivo</i>
2023Open Access
Supplementary Table S4 from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <i>In Vivo</i>
2023Open Access
Data from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <i>In Vivo</i>
2023Open Access
Supplementary Table S1 from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <i>In Vivo</i>
2023Open Access
Supplementary Table S2 from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <i>In Vivo</i>
2023Open Access
Supplementary Figure S3 from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <i>In Vivo</i>
2023Open Access
Supplementary Figure S3 from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <i>In Vivo</i>
2023Open Access
Supplementary Figure S1 from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <i>In Vivo</i>
2023Open Access
Supplementary Figure S2 from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <i>In Vivo</i>
2023Open Access
Supplementary Table S4 from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <i>In Vivo</i>
2023Open Access
Supplementary Figure S4 from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <i>In Vivo</i>
2023Open Access
Supplementary Table S1 from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <i>In Vivo</i>
2023Open Access
Supplementary Table S3 from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <i>In Vivo</i>
2023Open Access
Supplementary Figure S1 from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <i>In Vivo</i>
2023Open Access
Supplementary Figure S2 from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <i>In Vivo</i>
2023Open Access
Supplementary Table S2 from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <i>In Vivo</i>
2023Open Access
Supplementary Figure Legends from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <i>In Vivo</i>
2023Open Access
Data from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <i>In Vivo</i>
2023Open Access
page 1 of 2Next →

Frequent Co-authors

Adrian Wiestner(28), Mohammed Farooqui(27), Jade Jones(24), Deanna H. Wong(21), Sarah E. M. Herman(16), Sarah E.M. Herman(12), Jennifer Gyamfi(4), Stefania Pittaluga(2), Andrew Lipsky(2), Nakhle S. Saba(2), Sabrina Martyr(2), Gerald E. Marti(2), Georg Aue(2), Janet Valdez(2), Susan Soto(2), Stella Chang(1), Betty Chang(1), Carsten Utoft Niemann(1), Mahfooz Farooqui(1), Jeffrey A. Jones(1)